CLAIM AMENDMENTS

Listing of Claims:

Claims 1-33 (canceled)

Claim 34 (currently amended): A macrocyclic compound of the formula (1):



(1)

and its pharmaceutically acceptable salts,

wherein

Fragment A_1 is:

~~(1-i)~~



wherein

Y is H, ~~selected from the group consisting of~~

X_1 is -CH-, and

R_1 is



or



;



and

X_1 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_1 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_1 is absent;

when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of





Fragment A_2 is:

~~(2-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline, D-4-tert--butoxyproline, L-4-tert-butoxyproline; or~~

~~(2-ii)~~



wherein

X_2 is -CH-, and

R_2 is H;

~~X2 is -CH-, -(CH2)2- or -(CH2)3-;~~

~~when X2 is -(CH2)2- or -(CH2)3-, R2 is absent;~~

~~when X2 is -CH-, R2 is a radical independently selected from the group consisting of~~



Fragment A_3 is:

~~(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert- butoxyproline, *L*-4-tert-butoxyproline; or~~

~~(3-ii)~~



wherein

X_3 is -CH-, and

R_3 is



;

~~X3 is -CH-, -(CH2)2- or -(CH2)3-;~~

~~when X3 is -(CH2)2- or -(CH2)3-, R3 is absent;~~

~~when X3 is -CH-, R3 is a radical independently selected from the group consisting of~~





~~W_1 to W_{16} are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;~~

W_1, W_2, W_3, and W_5 are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:





and

;

wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 35 (currently amended): A macrocyclic compound of the formula (1) as defined in claim 34, wherein W_1, W_2, W_3, and W_5 are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:



~~and its pharmaceutically acceptable salts,~~

~~wherein~~

~~Fragment A1 is:~~

~~(1-i)~~



~~wherein~~

~~Y is selected from the group consisting of~~





~~X1 is -CH-, -(CH2)2- or -(CH2)3-;~~

~~when X1 is -(CH2)2- or -(CH2)3-, R1 is absent;~~

~~when X1 is -CH-, R1 is a radical independently selected from the group consisting of~~





~~Fragment A_2 is:~~

~~(2-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline, D-4-tert--butoxyproline, L-4-tert-butoxyproline; or~~

~~(2-ii)~~



~~wherein~~

~~X_2 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;~~

~~when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;~~

~~when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of~~





~~Fragment A_3 is:~~

~~(3-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline, D-4-tert-butoxyproline, L-4-tert-butoxyproline; or~~

~~(3-ii)~~



~~wherein~~

~~X_3 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;~~

~~when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;~~

~~when X_3 is -CH-, R_3 is a radical independently selected from the group consisting of~~



~~W_1 to W_{16} are each selected from the group consisting of hydrogen, and a compatible protecting group chosen from:~~





or 

~~Fragment T is a radical selected from the group consisting of:~~





~~wherein (N) indicates the site of a covalent bond to the nitrogen atom of A1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A3 of formula (1).~~

Claim 36 (currently amended): A macrocyclic compound of the formula (1) as defined in claim 34, wherein W_1, W_2, W_3, and W_5 each represents hydrogen.~~:~~



~~(1)~~

~~and its pharmaceutically acceptable salts,~~

~~wherein~~

~~Fragment A_1 is:~~



~~(1-i)~~

~~wherein~~

~~X_1 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;~~

~~when X_1 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_1 is absent;~~

~~when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of:~~





~~Fragment A_2 is:~~

~~(2-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline; or~~

~~(2-ii)~~



~~wherein~~

~~X_2 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;~~

~~when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;~~

~~when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of~~





~~Fragment A_3 is:~~

~~(3-i) D-proline, L-proline, D-4-hydroxyproline, L-4-hydroxyproline; or~~

~~(3-ii)~~



~~wherein~~

~~X_3 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;~~

~~when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;~~

~~when X_3 is -CH-, R_3 is a radical independently selected from the group consisting of~~



~~Fragment T is a radical selected from the group consisting of:~~





;

~~wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).~~

Claim 37 (new): A library of compounds, comprising at least five compounds selected from the group consisting of compounds represented by formula (1):



(1)

and its pharmaceutically acceptable salts,

Fragment A_1 is:

(1-i)



wherein

Y is selected from the group consisting of

H ,  ,  ,  ,

 ,  ,  and  ;

X_1 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_1 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_1 is absent;

when X_1 is -CH-, R_1 is a radical independently selected from the group consisting of





Fragment A_2 is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)



wherein

X_2 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_2 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_2 is absent;

when X_2 is -CH-, R_2 is a radical independently selected from the group consisting of



Fragment A_3 is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)



wherein

X_3 is -CH-, $-(CH_2)_2-$ or $-(CH_2)_3-$;

when X_3 is $-(CH_2)_2-$ or $-(CH_2)_3-$, R_3 is absent;

when X_3 is -CH-, R_3 is a radical independently selected from the group consisting of



;

W_1 to W_{16} are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

Fragment T is a radical selected from the group consisting of:



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A_1 of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A_3 of formula (1).

Claim 38 (new): The library according to claim 37, wherein in each compound W_1, W_2, W_3, and W_5 are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:



Claim 39 (new): The library according to claim 38, wherein in each compound W_1, W_2, W_3, and W_5 each represents hydrogen.

Claim 40 (new): A method of screening for a compound having antibacterial, antifungal, antiviral, or antineoplastic activity, which comprises:

a) providing the library of compounds according to claim 37; and

b) assaying the library of compounds against an etiological agent to identify compounds having antibacterial, antifungal, antiviral, or antineoplastic activity.

Claim 41 (new): The method of claim 40, wherein the etiological agent is selected from bacterial, fungal, viral, and neoplastic disease agents.

Claim 42 (new): An assay kit for the identification of compounds having antibacterial, antifungal, antiviral, or antineoplastic activity, the assay kit comprising a library according to claim 37, disposed in a plurality of vessels, wherein each vessel contains a compound of the library.